Isotechnika Pharma Inc. today announced that results of the international Phase 2/3 clinical trials studying voclosporin, conducted by its partner Lux Biosciences, were the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27.
Original post:
Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
You must log in to post a comment.